For teams planning a gout or hyperuricemia program, the central design questions are settled by precedent rather than guesswork: which biochemical endpoint FDA will accept as registrational, what serum urate threshold and responder definition to build powering around, whether an active or placebo comparator is expected, and how long pivotal treatment must run. Getting these choices aligned with prior approvals is what separates a defensible development plan from an avoidable end-of-phase-2 disagreement.
The analysis below walks through the urate-lowering therapies FDA has approved and reconstructs, program by program, the trial design each was cleared on — the primary efficacy endpoint and its serum urate target, the choice of comparator, the role of flares and tophus measures as secondary endpoints, and the treatment duration. It maps both the shared endpoint logic across the class and the points where individual programs diverged.
Want Rhizome's help on your own question? Try it for free.
FDA-accepted endpoints and trial designs for urate-lowering therapies in gout
Across the modern urate-lowering therapies (ULTs) approved by FDA, the pivotal efficacy question has been remarkably consistent: can the drug drive serum (or plasma) uric acid below a defined biochemical threshold and keep it there? Every approved program has been built on a serum urate (sUA) target endpoint rather than a clinical outcome such as flare rate or joint damage, with flares, tophus resolution, and safety carried as secondary or supportive measures. What differs across programs is the sUA threshold, the responder definition, the comparator, and the treatment duration. This overview walks through each approved program and what FDA accepted.
The shared endpoint logic: serum urate as the registrational target
The therapeutic rationale for gout ULTs is that sustained lowering of sUA below the saturation point for monosodium urate dissolves crystal deposits and, over time, reduces flares and tophi. FDA has accordingly accepted the proportion of patients reaching a specified sUA target as the primary efficacy endpoint in each pivotal program, with 6.0 mg/dL as the recurring threshold 52536826. The variations below reflect the mechanism and target population of each drug.
Febuxostat (Uloric, NDA 021856, original approval February 13, 2009)
Febuxostat, a xanthine oxidase inhibitor, was approved on the strength of three randomized, controlled Phase 3 trials that used an active comparator (allopurinol) in addition to, in one case, placebo 2152.
- Study C02-009 (Trial 009): randomized, double-blind, multicenter, parallel-group, dose-response study with five arms — febuxostat 80 mg, 120 mg, and 240 mg, allopurinol 300/100 mg once daily, and placebo. Randomization was skewed toward the active arms (roughly 1:2:2:1:2), treatment ran 28 weeks after washout, and 8 weeks of gout flare prophylaxis was included. The primary endpoint was the proportion of subjects whose last three sUA levels were <6.0 mg/dL 61524846.
- Study C02-010 (Trial 010): randomized, double-blind, parallel, three-arm, active-controlled study (febuxostat 80 mg, febuxostat 120 mg, allopurinol 300 mg) with no placebo arm, treated for 52 weeks with 8 weeks of flare prophylaxis. Same primary endpoint (last three sUA levels <6.0 mg/dL) 6352.
- Study F-GT06-153 (F-153): a 6-month, randomized, active-controlled study of febuxostat 40 mg and 80 mg versus allopurinol, stratified by renal function, with allopurinol dosed 300 mg daily in normal renal function and 200 mg daily in renal impairment. The primary endpoint was the proportion of patients with sUA <6 mg/dL at the final visit; randomization was 1:1:2 536455.
Two features are worth flagging for anyone designing an XOI program: FDA accepted allopurinol as an active comparator (not just placebo), and the endpoint used a multi-timepoint sUA criterion (the last three measurements) rather than a single visit, which raises the durability bar for the response.
Pegloticase (Krystexxa, BLA 125293, original approval September 14, 2010)
Pegloticase, a recombinant pegylated uricase given intravenously, targets patients with chronic gout refractory to conventional therapy, so its program was placebo-controlled rather than allopurinol-controlled 1227.
- Design: two replicate multicenter, randomized, double-blind, placebo-controlled, parallel-group studies (C0405 and C0406) in adults with symptomatic gout and hyperuricemia refractory to or intolerant of allopurinol. Patients were randomized 2:2:1 to pegloticase 8 mg IV every 2 weeks, every 4 weeks, or placebo, stratified by presence or absence of tophi. The controlled treatment period was 6 months (26 weeks), including 24 weeks of treatment after screening 2732333538.
- Primary endpoint: the proportion of subjects achieving and maintaining plasma uric acid <6 mg/dL for at least 80% of the time during Months 3 and 6 combined; a subject exceeding that 80% threshold was classified as a responder. The primary analysis was in the ITT population by Fisher's exact test versus placebo, with non-responder imputation for missing data 2628293442.
The "durable responder" construction (sUA <6 mg/dL for ≥80% of a defined window) is a more stringent, time-integrated endpoint than a single-visit target and reflects the biologic's episodic-infusion mechanism and anti-drug-antibody-driven loss of response.
Lesinurad (Zurampic, NDA 207988, original approval December 22, 2015)
Lesinurad, a URAT1 inhibitor that increases uric acid excretion, was developed as add-on therapy to a xanthine oxidase inhibitor rather than as monotherapy, and its Phase 3 program was built around that combination logic 146877.
- Studies 301 and 302: replicate 12-month, randomized, double-blind, multicenter, placebo-controlled add-on studies in patients with an inadequate response to allopurinol. Patients continued stable allopurinol and were randomized to lesinurad 200 mg, lesinurad 400 mg, or placebo on top. The primary endpoint was the proportion of patients with sUA <6.0 mg/dL by Month 6 68717277.
- Study 304: a 12-month, randomized, double-blind, placebo-controlled add-on study in patients on febuxostat 80 mg (after a 21-day run-in), randomized to lesinurad 200 mg, lesinurad 400 mg, or placebo. Here the primary endpoint used a lower target — proportion with sUA <5.0 mg/dL by Month 6 — reflecting the more intensive combination and a tophaceous population 6877.
Two design points stand out: the comparator was placebo layered on an active background XOI (an add-on architecture, not head-to-head monotherapy), and FDA accepted a Month 6 sUA readout within a 12-month study, with the threshold tuned to the background therapy (6.0 mg/dL on allopurinol, 5.0 mg/dL on febuxostat) 68717277.
Lesinurad/allopurinol fixed-dose combination (Duzallo, NDA 209203, approval August 18, 2017)
Duzallo illustrates a bridging strategy rather than a fresh efficacy program. FDA's review states the fixed-dose combination's efficacy and safety were "primarily predicated" on the previously reviewed lesinurad data from NDA 207988, with no new clinical efficacy trials submitted for the combination 1323.
- Supporting efficacy: the two Phase 3 randomized, placebo-controlled lesinurad-plus-allopurinol studies (the 301/302 program), comparator placebo on background allopurinol 200 to 900 mg daily, with roughly 405, 401, and 407 patients in the lesinurad 200 mg, 400 mg, and placebo arms; treatment ran up to 12 months (median about 11.2 months) 222425.
- Endpoint: the supporting trials evaluated the sUA <6 mg/dL target 23. The exact endpoint timepoint was not captured in the review pages retrieved here, but it maps to the Month 6 sUA <6.0 mg/dL primary endpoint of the underlying lesinurad studies 6871.
- New data for the FDC itself: a Phase 1 randomized, open-label crossover relative-bioavailability and food-effect study (RDEA594-501) in healthy volunteers, used for PK/bioequivalence bridging to the co-administered products, not for efficacy 23.
For regulatory strategists, Duzallo is a clean example of a 505(b)(2)-style FDC approval leaning on established component data plus a PK bridge, avoiding a duplicate outcome trial.
Cross-program synthesis
| Program | Mechanism / setting | Comparator | Primary endpoint | sUA target | Pivotal duration |
|---|---|---|---|---|---|
| Febuxostat (Uloric) | XOI monotherapy | Allopurinol (+ placebo in one study) | Proportion with last 3 sUA <6.0 mg/dL (final visit in F-153) | <6.0 mg/dL | 28 wk, 52 wk, and 6 mo 616353 |
| Pegloticase (Krystexxa) | IV uricase, refractory gout | Placebo | Durable responder: plasma UA <6 mg/dL ≥80% of Months 3 and 6 | <6.0 mg/dL | 6 mo (26 wk) 2726 |
| Lesinurad (Zurampic) | URAT1 inhibitor, add-on to XOI | Placebo on background XOI | Proportion with sUA below target by Month 6 | <6.0 mg/dL (allopurinol add-on); <5.0 mg/dL (febuxostat add-on) | 12 mo 6877 |
| Duzallo (lesinurad/allopurinol FDC) | FDC, bridged | Placebo on background allopurinol (bridged data) | sUA target (Month 6, per underlying studies) | <6.0 mg/dL | up to 12 mo 2223 |
Several throughlines are useful for planning a new ULT program:
- The registrational endpoint is biochemical, not clinical. FDA has repeatedly accepted the proportion of patients reaching an sUA threshold as the primary efficacy measure across XOIs, uricosurics, and uricase 526826. Flares and tophus resolution appear as secondary or supportive endpoints.
- 6.0 mg/dL is the anchor threshold, but it is context-dependent. The target tightened to 5.0 mg/dL when lesinurad was added to febuxostat, signaling that FDA will accept a more aggressive target where the background therapy and population justify it 68.
- Comparator choice tracks the population. Monotherapy XOI development used an active comparator (allopurinol); refractory and add-on programs used placebo, in the latter case layered on an active background agent 616827.
- Study duration ran from 6 months to 12 months, with the primary sUA readout often taken at Month 6 even in the 12-month studies, and flare prophylaxis built into the XOI trials 636827.
- Responder definitions vary in stringency. Pegloticase's time-integrated "≥80% of Months 3 and 6" responder rule and febuxostat's "last three sUA levels" criterion are more demanding than a single-visit threshold, and both were accepted 2652.
A reader building a specific development plan would want to follow up on the exact secondary-endpoint hierarchies (flare incidence windows, tophus count methodology), the CV safety expectations that later attached to febuxostat, and how the Month 6 versus end-of-study timepoints were handled statistically — all of which Rhizome can pull directly from the underlying FDA reviews.